hrcak mascot   Srce   HID

Pregledni rad


Davor Miličić
Boško Skorić

Puni tekst: hrvatski, pdf (240 KB) str. 0-0 preuzimanja: 538* citiraj
APA 6th Edition
Miličić, D. i Skorić, B. (2011). ASPIRINSKA REZISTENCIJA. Liječnički vjesnik, 133 (9-10), 0-0. Preuzeto s
MLA 8th Edition
Miličić, Davor i Boško Skorić. "ASPIRINSKA REZISTENCIJA." Liječnički vjesnik, vol. 133, br. 9-10, 2011, str. 0-0. Citirano 01.11.2020.
Chicago 17th Edition
Miličić, Davor i Boško Skorić. "ASPIRINSKA REZISTENCIJA." Liječnički vjesnik 133, br. 9-10 (2011): 0-0.
Miličić, D., i Skorić, B. (2011). 'ASPIRINSKA REZISTENCIJA', Liječnički vjesnik, 133(9-10), str. 0-0. Preuzeto s: (Datum pristupa: 01.11.2020.)
Miličić D, Skorić B. ASPIRINSKA REZISTENCIJA. Liječnički vjesnik [Internet]. 2011 [pristupljeno 01.11.2020.];133(9-10):0-0. Dostupno na:
D. Miličić i B. Skorić, "ASPIRINSKA REZISTENCIJA", Liječnički vjesnik, vol.133, br. 9-10, str. 0-0, 2011. [Online]. Dostupno na: [Citirano: 01.11.2020.]

Although present in pharmacotherapy for more than 100 years, aspirin still represents a cornerstone in the primary and secondary prevention of cardiovascular patients. Despite undoubtful benefit, a certain proportion of patients treated with aspirin develops adverse atherothrombotic events like stent thrombosis, myocardial infarction, stroke and cardiovascular death. In recent years, there is a growing scientific interest concerning the relationship of suboptimal antiplatelet response to aspirin and cardiovascular prognosis that has led to the concept of »aspirin resistance«. Besides the absence of uniform definition of aspirin resistance, an important issue in these studies are numerous and poorly standardized laboratory methods that are used in its detection. Despite an increasing number of reports that favour its clinical significance, there are still no expert recommendations for routine assessment of platelet aggregation as well as for modification of antiplatelet doses or regimens in the case of established aspirin resistance.

Ključne riječi
Aspirin – therapeutic use, pharmacology; Drug resistance; Platelet aggregation inhibitors – therapeutic use, pharmacology; Cyclooxygenase inhibitors – therapeutic use; Blood platelets – drug effects, physiology; Platelet function tests – methods; Cardiovascular diseases – drug therapy, complications; Thrombosis – prevention and control

Hrčak ID: 171855



Posjeta: 657 *